Betibeglogene autotemcel for treating transfusion-dependent beta-thalassaemia [ID968]

  • Discontinued
  • GID-TA10334
This appraisal has been suspended while Bluebird Bio explores how to give patients in Europe access to its gene therapies in light of its forthcoming operational changes. A further update will be provided by late autumn.